Daniel Mullins, PhD: How Biosimilars Are Impacting Costs

June 5, 2019

Daniel Mullins, PhD, chair of pharmaceutical health services research at the School of Pharmacy, University of Maryland, discusses how biosimilars are impacting the cost of care.

Transcript

Biosimilars are a real game-changer. In the same way that we've seen a reduction in price as we see traditional medicines going to branded, we're seeing the same thing with biosimilars.

If you would have asked me what am I potentially worried about, if you look back to the literature, when generics first came out to the market in the more expedited role, there was a generic drug scandal, and if anything were to happen where there were a biosimilar that was used that we found out really wasn't as good as the originator biologic, that could set biologics back.

But short of that, I really do believe that this is going to be good for the American public.

Related Content:

Interviews

x